ZZW-115
CAS No. 801991-87-7
ZZW-115( —— )
Catalog No. M37627 CAS No. 801991-87-7
ZZW-115 is a potent NUPR1 inhibitor with a Kd of 2.1 μM and is a derivative of Trifluoperazine (TFP).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 255 | In Stock |
|
| 5MG | 426 | In Stock |
|
| 10MG | 630 | In Stock |
|
| 25MG | 998 | In Stock |
|
| 50MG | 1274 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameZZW-115
-
NoteResearch use only, not for human use.
-
Brief DescriptionZZW-115 is a potent NUPR1 inhibitor with a Kd of 2.1 μM and is a derivative of Trifluoperazine (TFP).
-
DescriptionZZW-115 is a potent NUPR1 inhibitor, with a Kd of 2.1 μM. ZZW-115 induces tumor cell death by necroptosis and apoptosis. Anticancer activity.
-
In VitroZZW-115 (0.1-33 μM; 72 hours) is efficient in killing cancer cells, with an IC50 in the range of 0.84 μM (ANOR) to 4.93 μM (HN14).ZZW-115 (0-100 μM; 24-72 hours) is efficient to kill these tumor cells with an IC50 in the range of 0.42 μM (Hep2G cells) to 7.75 μM (SaOS-2 cells).ZZW-115 induces pancreatic cell death by necrosis and apoptosis. ZZW-115 treatment induces a decrease in ATP production and induces a ROS overproduction.LDH release is significantly higher in ZZW-115-treated cells (MiaPaCa-2, 02-063, LIPC, Foie8b, and HN14 cells) than in control cells in a concentration-dependent manner. Similarly, caspase 3/7 activity is also greater in ZZW-115-treated cells. These experiments demonstrated that ZZW-115 exerted both pronecrotic and proapoptotic effects.Cell Viability Assay Cell Line:ANOR cells, MiaPaCa-2, 02-063, 01008, LIPC, 02136, HN01,01046, AOIPC, Foie8b, HN14 cells Concentration:0.1- 33 μM Incubation Time:72 hours Result:Was efficient in killing cancer cells, with an IC50 in the range of 0.84 μM (ANOR) to 4.93 μM (HN14).Cell Proliferation Assay Cell Line:U87, A375, U2OS, SaOS-2, HT29, SK-CO-1, LS174T, H1299 and H358, HepG2, PC3, THP-1, Daudi, Jurkat and MDA-MB-231 cells Concentration:0-100 μM Incubation Time:24 or 72 hours Result:Was efficient to kill these tumor cells with an IC50 in the range of 0.42 μM (Hep2G cells) to 7.75 μM (SaOS-2 cells).
-
In VivoZZW-115 (0.5-5 mg/kg; injection; daily for 30 days) inhibits the growth of pancreatic xenografted tumors.ZZW-115 (5 mg/kg for 30 days; immunocompetent C57BL/6 mice were orthotopically implanted with Panc02 cells) treatment shows the tumor size is almost unmeasurable in some cases.Animal Model:NMRI-Foxn1nu/Foxn1nu mice (nude mice) xenografted with MiaPaCa-2 cells Dosage:5, 2.5, 1.0, or 0.5 mg/kg Administration: Injection, daily for 30 days Result:When the mice were injected with 5 mg/kg ZZW-115, the tumors stopped growing a few days after treatment and their size decreased progressively, almost disappearing at the end of the treatment.
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number801991-87-7
-
Formula Weight464.59
-
Molecular FormulaC24H31F3N4S
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESC(CCN1CCN(CCN(C)C)CC1)N2C=3C(SC=4C2=CC=CC4)=CC=C(C(F)(F)F)C3
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Santofimia-Casta?o P, et al. Ligand-based design identifies a potent NUPR1 inhibitor exerting anticancer activity via necroptosis. J Clin Invest. 2019;129(6):2500-2513. Published 2019 Mar 28.?
molnova catalog
related products
-
Ingenol
Ingenol mebutate is an effective treatment for actinic keratosis. 2. Formulating novel derivatives from Ingenol esters may be an innovative approach to develop new lead compounds to reactivate latent HIV.
-
(Nle8·18,Tyr34)-pTH ...
(Nle8·18,Tyr34)-pTH (7-34) amide (bovine)
-
DRB18
DRB18 is a highly effective pan-class inhibitor of glucose transporter proteins (GLUT). It significantly modulates energy-related metabolism in A549 cells by inducing alterations in the abundance of metabolites associated with glucose-related pathways.
Cart
sales@molnova.com